SPRY — ARS Pharmaceuticals Balance Sheet
0.000.00%
- $811.55m
- $619.57m
- $89.15m
- 53
- 15
- 21
- 19
Annual balance sheet for ARS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 387 | 254 | 274 | 228 | 314 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 9.16 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 391 | 261 | 278 | 232 | 334 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.8 | 6.95 | 0.774 | 0.824 | 1.07 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 395 | 333 | 281 | 233 | 351 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.6 | 14.9 | 5.44 | 2.39 | 23.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.9 | 19.7 | 8.55 | 2.43 | 94.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 383 | 314 | 273 | 231 | 257 |
| Total Liabilities & Shareholders' Equity | 395 | 333 | 281 | 233 | 351 |
| Total Common Shares Outstanding |